Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8178563 | SUN PHARM | Compounds and compositions as hedgehog pathway modulators |
Jul, 2029
(6 years from now) | |
US8063043 | SUN PHARM | Salts of N-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide |
Sep, 2029
(6 years from now) | |
US10266523 | SUN PHARM | Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4′-(trifluoromethoxy) [1,1′-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof |
Mar, 2036
(12 years from now) |
Market Authorisation Date: 24 July, 2015
Treatment: Treatment of basal cell carcinoma
Dosage: CAPSULE;ORAL
14
United States
6
China
4
Japan
4
Argentina
4
European Union
3
Korea, Republic of
3
Spain
3
Portugal
3
Poland
3
Norway
3
Brazil
2
Ecuador
2
Australia
2
EA
2
El Salvador
2
Israel
2
Canada
2
New Zealand
2
Denmark
2
Honduras
2
Tunisia
2
Peru
2
Malaysia
2
Costa Rica
2
Chile
2
Cyprus
2
Jordan
2
Ukraine
2
Morocco
2
Hong Kong
2
San Marino
2
Mexico
2
Georgia
2
Cuba
2
South Africa
2
Slovenia
2
Taiwan
1
Colombia
1
Luxembourg
1
Croatia
1
Dominican Republic
1
Netherlands
1
Nicaragua
1
ME
1
Singapore
1
Russia
1
Guatemala
1
Hungary
1
Lithuania
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic